Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

Chronic urticaria (CU) is a dermatological condition characterized by recurrent wheals (hives), angioedema (deep tissue swelling), or both, persisting for over 6 weeks. 1 Unlike acute urticaria ...

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Remibrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria in two identical randomized ...